Q-omics provides the consensus-scored BTF3P7 profile across patient tissues and cancer cell-line models. BTF3P7 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, BTF3P7 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, BTF3P7 RNA expression shows 10,585 significant protein co-abundance associations, with the highest sampling consensus in OV. Together, these results highlight STAD, KIRC, and OV as cancer lineages where BTF3P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTF3P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTF3P7 survival associations across molecular data types. BTF3P7 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTF3P7 RNA expression–survival associations across cancer types. High BTF3P7 expression shows unfavorable associations in STAD, KIRP and LGG, but favorable associations in CESC, KIRC and READ. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for BTF3P7 RNA expression.
This table summarizes BTF3P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BTF3P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTF3P7 shows lower tumor expression in HNSC and higher tumor expression in KIRC, COAD, LUAD, BRCA and LIHC. The KIRC box plot shows higher BTF3P7 RNA expression in tumor versus normal tissue (log2 FC = +0.310, t-test p < 0.001).
This table shows molecular features associated with BTF3P7 in patient tissues and cancer cell lines. In patient samples, BTF3P7 shows the broadest associations at the RNA and protein expression levels, with OV recurring as the lineage with the largest associated feature set.
